Institutional members access full text with Ovid®

Share this article on:

Ceftaroline: Place in Therapy Compared to the Available Intravenous Cephalosporins

Johnson, Steven W. PharmD*†; May, D. Byron PharmD*

Infectious Diseases in Clinical Practice: January 2014 - Volume 22 - Issue 1 - p 8–17
doi: 10.1097/IPC.0b013e3182948d1c
Review Articles

Abstract: Cephalosporins are widely used antibiotics throughout the world. However, with the availability of multiple agents in this class with varying spectrum of activity and clinical use, selecting the most appropriate cephalosporin can become convoluted. Ceftaroline, a new-generation cephalosporin recently approved in the United States for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection may further complicate this dilemma. Ceftaroline is easily distinguishable compared to the other intravenous cephalosporins given its activity against methicillin-resistant Staphylococcus aureus (MRSA) including multidrug-resistant MRSA. Unfortunately, its Food and Drug Administration–approved indications offer little benefit for the antimicrobial, given cheaper, oral, and more experienced antimicrobials for these indications exist. Ceftaroline may be more appealing in the treatment of infections that require broad-spectrum intravenous antibiotics empirically (eg, endocarditis, meningitis, and osteomyelitis), especially if MRSA is a concern. However, future studies are needed to evaluate its efficacy for these indications. Until these are completed, ceftaroline should be considered as an alternative for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection at this time.

From the *Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC; and †Forsyth Medical Center, Winston-Salem, NC.

Correspondence to: Steven W. Johnson, PharmD, BCPS, Forsyth Medical Center, 1612 Barndale Glen Ct, Winston-Salem, 27106. E-mail:;

The authors have no funding or conflicts of interest to disclose.

© 2014 Wolters Kluwer Health, Inc. All rights reserved.